Quoin Pharmaceuticals Ltd. (QNRX) Tuesday said that it has received Orphan Drug Designation in Europe by the European Medicines Agency (EMA) for its lead drug candidate QRX003 in Netherton Syndrome. Orphan Drug Designation in Europe offers various benefits including reduced fees, market exclusivity, and access to scientific advice.
QRX003 is currently being evaluated in multiple late-stage studies in Netherton Syndrome.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.